Reported 2 days ago
Corcept Therapeutics (CORT) is highlighted as one of the best-performing healthcare stocks, ranking eighth among its peers with a year-to-date performance of 39.37%. The company specializes in therapies that modulate cortisol effects and has potential for growth, particularly with its flagship product Korlym and its expansion into oncology. Analysts remain optimistic despite recent operational challenges, suggesting that current market conditions present a compelling buying opportunity.
Source: YAHOO